RecruitingNot ApplicableNCT05493605

Cardiac Involvement in Wilson's Disease


Sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Enrollment

150 participants

Start Date

Mar 2, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia. This could suggest that the clinical manifestations related to the copper accumulation in the heart appears with the duration of the disease. Case-control studies on adult populations have highlighted various electrocardiographic (ECG) abnormalities more frequent in patients with Wilson's Disease than in healthy volunteers, but all these studies involved small number of patients (maximum 60). The hypothesis is that there is cardiac involvement in Wilson's Disease, requiring screening, follow-up and appropriate support.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Adult patient with Wilson's disease confirmed by a Leipzig score ≥ 4
  • Express consent to participate in the study by the patient or legal guardian in the case of patients under guardianship or by the patient assisted by his curator in the case of patients under guardianship
  • Member of or beneficiary of a Social Security scheme

Exclusion Criteria4

  • Absolute or relative contraindication to MRI or contrast media
  • Pregnant, parturient or breast-feeding women: a urine pregnancy test will be carried out in women of childbearing age
  • Patient with hepatic decompensation (Child-Pugh score stage C)
  • Patient in neuro-psychiatric decompensation

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREDelivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope

The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.


Locations(1)

Fondation Adolphe de Rothschild

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05493605


Related Trials